Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury
10.16438/j.0513-4870.2017-0315
- VernacularTitle:免疫调控与特异质型药物性肝损伤发生机制研究进展
- Author:
Zhao-fang BAI
1
;
Yuan GAO
1
;
Xiao-bin ZUO
1
;
Jia-Bo WANG
1
;
Xiao-he XIAO
2
Author Information
1. China Military Institute of Chinese Materia, 302 Military Hospital, Beijing 100039, China
2. Integrative Medical Center, 302 Military Hospital, Beijing 100039, China
- Publication Type:SPECIAL REPORTS
- Keywords:
idiosyncratic drug-induced liver injury;
immune regulation;
chemical medicine;
traditional Chinese medicine;
mechanism hypothesis
- From:
Acta Pharmaceutica Sinica
2017;52(7):1019-1026
- CountryChina
- Language:Chinese
-
Abstract:
Idiosyncratic drug-induced liver injury(IDILI)is an adverse drug reaction that occurs only in a minority of the population. IDILI also has many characteristics such as unpredictable and low morbidity, its occurrence has often not been clearly correlated with the dose, route, or duration of drug administration. Several studies have shown that IDILI is a synergistic effect which was caused by body diathesis, environment and drugs. In addition, evidence also suggests that most IDILIs are mediated by immunity. Chemical medicines-related IDILIs have been extensively studied, and a variety of immunological mechanism hypotheses have also emerged to explain the pathogenesis and characteristics of chemical medicines-related IDILIs. However, the traditional Chinese medicine(TCM)-related IDILI has always been neglected due to the complexity and specificity of TCM. In recent years, TCM-related IDILI has been gradually confirmed by researchers, and formed a new hypothesis, a immunological stress-mediated tri-elements synergetic mechanism hypothesis, which can reveal the pathogenesis and clinical characteristics of TCM-related IDILI. This paper is prepared to summarize the immunological mechanism hypotheses of chemical medicine-related IDILI and TCM-related IDILI to provide a scientific basis for guiding IDILI research and establishing its clinical risk prevention and control measures.
